Abstract Purpose: Although the function of natural killer receptors on T cells infiltrating tumors and their potential effect on antitumor immunity has been investigated, little is known about Tcells expressing NKR-P1A (CD161) in cancer patients. In the present study, we examined T cells expressing CD161in the peripheral blood, the tumor tissue and in malignant effusions of patients with several types of malignancies. Experimental Design: Expression of CD161 in CD4 + or CD8 + (lacking CD56) T cells isolated from peripheral blood (n = 61), tumor specimens (n = 8), and malignant effusions (n = 37) of cancer patients was examined using four-color flow cytometry. Proliferative capacity and cytokine production of purified CD4 + CD161 + CD56 À cells were studied after weak or strong stimulation, with or without costimulation, in the presence or absence of interleukin 2. The possible regulatory function of activated CD4 +
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À cells on T-cell alloresponses was also investigated. During the last decade, attention has focused on the expression of activating and inhibitory receptors of natural killer (NK) cells on T-cell subsets. Both types of NK receptors, namely killer cell immunoglobulin-like receptors and C-type lectin receptors, have been detected on peripheral T lymphocytes (1 -6) , as well as on tumor infiltrating lymphocytes in melanoma (7 -9) , renal cell carcinoma (10, 11) , and cervical carcinoma patients (12) . The potential role of inhibitory NK receptor on T-cell function has been extensively examined, whereas the concept that NK receptors are involved in the dysfunction of T lymphocytes against cancer cells has been established as a novel escape mechanism of tumors from immunosurveillance. Human NKR-P1A (CD161) is a type II transmembrane glycoprotein with characteristics of the C-type lectin superfamily, lacking a clear ITIM/ITAM (immunoreceptors tyrosine-based inhibitory/activating) motif. Although CD161 is considered a receptor of NK cells, it is also expressed on 25% of adult peripheral T cells, mostly of effector/memory phenotype (6) . It has also been detected on >90% of peripheral blood monocytes and in vitro derived dendritic cells (13) . Engagement of CD161 on the latter cell population results in strong intracellular calcium release, as well as in IL-1h and IL-12 production (13) .
A small subset of T cells coexpressing CD161 and an invariant Va24JaQ T-cell receptor (TCR) a chain, paired predominantly with Vh11, is defined as analogous to murine NK1.1 + T cells and possesses immunoregulatory features through production of both Th1 and Th2 cytokines. CD161 on this subset has been reported to function as a costimulatory molecule (14) . Nevertheless, Va24 + CD161 + cells represent only a minority (0.01-0.1%) among peripheral blood T cells (15) . In contrast, CD161 + T cells (mostly CD8 + ), not skewed to Va24 TCR, were found to accumulate in human liver and were able to exhibit strong cytotoxicity against various tumor cell lines (16) . Over one half of T cells (either CD4 or CD8), isolated from epithelial and lamina propria layers of duodenum and colon, express CD161 and are capable of producing IFN-g and tumor necrosis factor-a, but not IL-4, upon activation with phorbol 12-myristate 13-acetate and ionomycin (17 
Materials and Methods
Patients and normal donors. Heparinized blood samples were collected from 12 healthy donors and 61 cancer patients (47 breast cancer, 4 ovarian, 4 lung, 2 colon, 2 pancreas, and 2 stomach). Tumor samples from eight breast cancer patients were obtained by surgical excision. MEs from 37 cancer patients (25 ascites and 12 pleural effusions) were also collected during routine aspirations. Information regarding patients' type of cancer and tumor stage (according to the American Joint Committee on Cancer) was also recorded. All samples have been acquired under the informed consent of patients and normal donors, according to the Declaration of Helsinki.
Cell isolation. PBMCs were isolated by Ficoll-Hypaque centrifugation using standard procedures. Tissue obtained from tumor specimens of breast cancer patients was mechanically fragmented with scissors and scalpel. The resulting small pieces were digested for 2 to 4 hours in MEM-a (Life Technologies, Ltd., Paisley, Scotland) with 5 mg/mL collagenase IV (Life Technologies). A part of the cells acquired, after three washes in HBSS (Life Technologies), was used for flow cytometry and the remaining cells were kept frozen in liquid nitrogen. MEs (250-1,000 mL) were spun at 1,300 rpm (rounds per minute) for 10 minutes. Part of the cells acquired (MNC and cancer cells) were used for flow cytometry or further cell isolations and the remaining cells were kept frozen in liquid nitrogen.
Flow cytometry. The phenotype of lymphocytes isolated from peripheral blood, tumor specimens, and MEs was determined using four-color flow cytometry. Monoclonal antibodies (mAb) specific for CD3, CD8, CD45, CD45RA, CD45RO, CD25, CD38, CD95, HLA-DR conjugated with fluorescein isothiocyanate (FITC), CD4 conjugated with allophycocyanin (APC), and isotype-matched controls were purchased from Becton Dickinson (Mountain View, CA). mAbs against CD161 (clone 191B8) conjugated with phycoerythrin (PE), and CD56 conjugated with PEcy5 were obtained from Immunotech (Marseilles, France). FITC-conjugated mAbs against TCR Vh2, Vh7, Vh11, Vh13.6, Vh14, Vh16, Vh18, Vh20, Vh21, Vh22, and Va24 were purchased from Serotec (Oxford, United Kingdom), whereas Vh3.1, Vh5(a), Vh6.7, Vh8(a), Vh12, and Vh13 were obtained from Endogen (Woburn, MA).
Cells to be immunostained were washed twice with ice-cold PBS (Life Technologies)/1% bovine serum albumin (Sigma, St. Louis, MO)/ 0.05% NaN 3 followed by incubation with saturating concentrations of the appropriate mAbs for 15 minutes at room temperature. Thereafter, cells were washed twice in ice-cold PBS/1% bovine serum albumin/ 0.05%NaN 3 ) were seeded into 96-well round-bottomed plates. T-cell expander beads (CD3/CD28 Dynabeads, Dynal Biotech, Oslo, Norway) or CD3 Dynabeads (Dynal Biotech) were added at a bead/cell ratio of 4:1 (strong signal) or a 1:10 (weak signal) in the presence or absence of 100 IU/mL IL-2 (Proleukin, Chiron B.V., Amsterdam, the Netherlands) and cultured for 72 hours. Proliferation of stimulated cells was estimated by adding 1 ACi Cytokine detection. Cytokine production was measured in supernatants of CD4 + CD161
+ cultures, seeded as described above. Supernatants were kept frozen at À75jC, until analysis. Levels of IFN-g, IL-10, IL-4, TNF-a, and granulocyte macrophage colony-stimulating factor (GM-CSF) were determined by multiplexed particle-based flow cytometric assay, according to the recommendations of the manufacturer (R&D Systems, Abington, United Kingdom). Transforming growth factor-h (TGF-h) secretion was measured by ELISA (R&D Systems), according to the instructions of the manufacturer.
Mixed lymphocyte reaction. PBMC (5 Â 10 4 per well) and irradiated (3 Â 10 4 per well; 3,000 rad) allogeneic lymphoblastoid cell line (LCL) were cocultured in 96-well round-bottomed plates. Autologous to PBMC-purified CD4 + CD161 + cells, strongly (four beads per cell) stimulated for 3 days with T-cell expander beads or CD3 beads in the absence or presence of 100 IU/mL IL-2, were treated with mitomycin C (Kyowa, Tokyo, Japan), as previously described (22) . Mitomycin Ctreated CD4 Statistical analysis. Statistical analysis was done with Graphpad Prism version 4.00 (Graphpad Software, Inc., San Diego, CA). Data were analyzed by Student's t test and Pearson coefficient analysis. P < 0.05 was considered significant. (Fig. 1A) .
Results
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Furthermore, PBMCs and MEs were obtained at the same time from 17 cancer patients and a positive correlation was observed in the percentage of CD4 + cells expressing CD161 between circulating and ME-MNC (r = 0.83, P < 0.001, Pearson coefficient; Fig. 1B 
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À gated cells, using four-color flow cytometry. Representative results from two donors out of five tested. C,TCRh repertoire was also examined in the peripheral blood (left) and ME (right) of three cancer patients. Representative results from one patient. 
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À cells (57 F 25 in normal donors' PBMC, 38 F 8.6 in patients' PBMC, and 38.5 F 9.2 in ME-MNC, P < 0.05).
As also shown in Fig. 2A , CD4 + CD161 À cells comprise a mixture of naBve (CD45RA + ) and memory (CD45RO + ) cells, characterized by variation in the expression of these markers among different types of samples. On the contrary, CD4 + CD161 + cells possess a defined memory phenotype with low CD45RA and high CD45RO expression, in agreement with previous reports (14, 21) . Intriguingly, significant decrease in CD4 + CD161 + cells expressing CD45RA was observed in ME-MNC (P < 0.01). The intensity of expression of CD45RA was also reduced in cancer patients' CD4 + CD161 + cells (mean MFI 92 F 27 in normal donors' PBMC, 58.6 F 36.9 in patients' PBMC, and 58.5 F 36.7 in ME-MNC, P < 0.05). The percentage of CD4 + CD161 + cells expressing CD45RO was similar in both normal donors and cancer patients.
To examine whether CD4 + CD161 + cells comprise an oligoclonal cell population, the TCR repertoire of gated CD4 + CD161 + cells was examined in five healthy donors as well as three cancer patients and compared with CD4 + CD161 À cells. As shown in Fig. 2B and C, CD4 + CD161 + cells were not biased toward a restricted TCR phenotype and therefore cannot be considered as oligoclonally expanded cells.
Proliferative capacity and activation signal requirements of isolated CD4 + CD161 + cells. Proliferative capacity and activation requirements of isolated CD4 + CD161 + cells were investigated in 3-day cultures in the presence of strong or weak signal via CD3/CD28 or CD3 alone, with or without IL-2. As shown in Fig. 3 , costimulation via CD28 considerably increased proliferation of CD4 + CD161 + cells compared with stimulation via CD3 alone (P < 0.01). In the absence of costimulation, strong TCR triggering or IL-2 presence were required for + CD161 + cells used in the proliferation assay were isolated using a specific mAb directed against CD161, triggering of this receptor might have occurred under all culture conditions tested. However, due to contradictory data concerning the effect of CD161 ligation with the used mAb, the actual role of this interaction on the isolated cell population cannot be estimated.
Cytokine production of activated CD4 + CD161 + cells. To investigate the effect of different stimulatory signals on the functional activity of CD4 + CD161 + populations, isolated cells from normal donors' peripheral blood and patients' MEs were + cells were found to produce overall higher amounts of cytokines, compared with CD4 + CD161 À cells (data not shown). The levels of cytokines produced highly varied from donor to donor, in both healthy individuals and cancer patients, although a similar pattern is observed, as far as their signal requirements for cytokine production is concerned. Isolated cells were capable of producing all cytokines tested, when costimulation via CD28 or IL-2 were provided. Production of Th1 and Th2 cytokines is expected because CD4 + CD161 + cells comprise a memory T-cell population. Different stimulation signals alter the amount of cytokines produced, but no effect on cytokine profile is observed. The amount of cytokines produced correlates with signal strength and reaches a maximum level in the presence of IL-2 and strong costimulation. Similar pattern in cytokine production is observed in both healthy individuals and cancer patients. As stated in the previous paragraph, the possible contribution of CD161 ligation with the mAb used for the isolation of this subpopulation cannot be evaluated under these conditions. TGF-h secretion was also examined in isolated CD4 + CD161 + cells after strong stimulation with anti-CD3/anti-CD28 beads and was found to reach 100.5 F 38 pg/mL (range 57.3-150) in four normal donors and 116 F 31 pg/mL (range 94-138) in cancer patient ME (data not shown). + cell ratios (Fig. 5) . CD4 + CD161 + cells, in these series of experiments, were pretreated with mitomycin C to prevent their proliferation. Freshly isolated CD4 + CD161 + cells had no suppressive activity on autologous PBMC proliferation (data not shown). However, when CD4 + CD161 + cells were previously stimulated for 3 days with a high concentration of CD3/CD28 beads, in the presence or absence of IL-2, suppression of autologous PBMC proliferation was achieved. This suppressive effect was not observed when CD4 + CD161 + cells were stimulated with CD3 beads alone. CD4 + CD161 + cells, stimulated via CD28, induced higher levels of suppression (44% F 4.2) in the absence rather than in the presence (26.6% F 3.2) of IL-2. These data suggest that CD4 + CD161 + cells may exert suppressive function on PBMC proliferation upon CD28 costimulation.
Suppressive activity of CD4 + CD161 + cells is partly mediated by soluble factors. Because CD4 + CD161 + cells, receiving strong costimulatory signals, secrete immunosuppressive cytokines (i.e., IL-10, IL-4 and TGF-h), we were interested to determine whether the suppressive function of cultured cells was mediated by these soluble factors. For this reason, MLR assays were done in which PBMC and allogeneic LCL were cultured in the lower section of transwell systems, whereas CD4 + CD161 + cells, previously stimulated for 3 days with high concentration of CD3/CD28 beads in the presence of IL-2, were added to the upper section at equal amounts with those of PBMC. 
+ cells (Fig. 5C ). The effect of IL-10, IL-4, and TGF-h on PBMC proliferation was estimated by adding neutralizing mAbs to investigate whether neutralization of these cytokines restores proliferation of PBMC. Neutralization of IL-10, IL-4, and TGF-h reduced the percentage inhibition to 58%, 66%, and 42%, respectively. The percentage suppression of patient PBMC proliferation was 79% when ME CD4 + CD161 + cells were added (Fig. 6B) . Neutralization of cytokines decreased this inhibition to 55%, 52%, and 45% when mAbs specific for IL-10, IL-4, and TGF-h were used in the MLR. When all neutralizing mAbs were added, inhibition was reduced to 26% in the normal donor (Fig. 6A) and 16% in the cancer patient (Fig. 6B) . These results indicate that the suppressive effect of CD4 + CD161
+ cells on autologous PBMC proliferation is dependent on soluble factors, mainly IL-10, IL-4, and TGF-h.
Discussion
In the present study, we report for the first time increased frequencies of CD4 À , followed by high expression of CD95, which is consistent with a memory phenotype, both in healthy + cells, previously stimulated for 3 days with high concentration (four beads per cell) of CD3/CD28 beads in the presence of 100 IU/mL IL-2, were added to the transwell inserts. For neutralization of IL-10, 10 Ag/mL anti-IL-10 mAb were added. Anti-IL4 or anti-TGF-h mAbs (1mg/mL) were used for IL-4 and TGF-h neutralization. Proliferation of PBMC was estimated after 4 days by [ donors and cancer patients. Increase of CD4 + cells expressing CD161 in cancer patients may be due to previous immune stimulation by tumor-associated antigens and acquisition of memory phenotype. However, the issue of tumor specificity of these cells remains to be elucidated. Peripheral blood CD4 + CD161
+ cells tested ex vivo were characterized by low expression of activation markers (CD25, CD38, HLA-DR), implying that they do not represent a currently activated T-cell population in vivo. On the contrary, CD4
+ CD161 + cells in ME, as well as CD4 + CD161
À , were found to comprise more activated cells, because both populations exhibited higher HLA-DR expression. Production of both Th1 and Th2 cytokines is also in agreement with the memory characteristics of these CD4 + CD161
+ cells. Furthermore, costimulation through CD28 is essential for proliferation and cytokine secretion of CD4 + CD161 + cells. In the absence of costimulation, proliferation of CD4 + CD161 + cells is almost undetectable, unless IL-2 or a strong TCR signal is provided.
The increase of CD4 + cells expressing CD161 in cancer patients prompted us to examine whether these cells are capable of exerting suppressive function and, therefore, may contribute to possible tumor escape from immune surveillance. In this respect, we found that only CD3/CD28 -stimulated cells were capable of significantly inhibiting autologous PBMC alloresponses. Additionally, the suppressive capacity of CD28-costimulated CD4 + CD161
+ cells did not require cell-to-cell contact, but was attributed to soluble factors, mainly IL-10, IL-4, and TGF-h. The above observations indicate that CD4 + CD161
+ cells may exert their immunoregulatory role mainly through cytokine secretion, depending on the microenvironment in which they develop. The natural ligand of human CD161 has been recently defined (24, 25) . Interaction of the human CD161 receptor with lectinlike transcript 1 triggers opposing signals on NK and T cells. Namely, CD161 ligation with lectin-like transcript 1 inhibits cytotoxicity and IFN-g production by NK cells, whereas simultaneous engagement of CD3 and CD161 on T cells enhances IFN-g production (24) . Lectin-like transcript 1 is expressed on a variety of cells types (monocytes, B cells, IL-2 activated NK or T cells, osteoclasts) and is considered the orthologue of murine Clr family genes, which are recognized by Nkr-p1 receptors (26, 27) . Apart from the potential suppressive effect of CD4 + CD161
+ cells through cytokine production, interactions of this population with other cells of the immune system, through lectin-like transcript 1, would be interesting to be elucidated.
Because the increase in CD4 + CD161 + cells is observed in all cancer patients independently of the chemotherapeutic scheme they receive, 4 it can be speculated that they may directly correlate with the clinical status of the patient and possibly their tumor burden. Nevertheless, apart from the biological function of CD4 + CD161
+ cells and the role they might play in tumor immunity, the fact that this cell population increases in cancer implies that determination of CD4 + CD161
+ frequency in peripheral blood might be used as a marker for the follow-up evaluation of cancer patients.
